Women's sexual health
Men's sexual health
NEW: Breakthrough Phase II Results for Women

Transforming Sexual Health

Bringing hope to millions with innovative, non-hormonal treatment solutions for sexual dysfunction

Scroll to explore
Our Mission

Pioneering Solutions for Sexual Health

Innovation First

Developing breakthrough non-hormonal therapies that address unmet medical needs in sexual health

Patient-Centered

Committed to improving quality of life for millions affected by sexual dysfunction worldwide

Science-Driven

Rigorous research and clinical validation ensuring safe, effective therapeutic solutions

BZ371A topical gel formulation
Our Approach to ED

Covering all ED Sufferers Alike

At Another Day Pharma, we're developing breakthrough peptide treatments for erectile dysfunction that work through a novel mechanism of action.

BZ371A works independently of neural pathways, offering hope for all men with ED—including those who don't respond to PDE5 inhibitors, post-prostatectomy patients, and those seeking enhanced efficacy through combination therapy.

2/3
Of men with ED don't respond to PDE5 inhibitors*
*Sildenafil, Tadalafil effective in only 1/3 of patients
230K+
Men undergo prostatectomy annually (US & EU)
*161,000 (US), 60,000-70,000 (EU)
Our Approach to FSIAD

Non-Hormonal Innovation for Women

At Another Day Pharma, we're pioneering the first effective non-hormonal treatment for Female Sexual Interest/Arousal Disorder (FSIAD).

Our research focuses on novel mechanisms of action that address the root causes of female sexual dysfunction, offering women safer, more effective alternatives to traditional hormonal approaches.

800M+
Women affected by FSD worldwide*
*~40% global prevalence
0
Approved non-hormonal treatments for FSIAD
BZ371A peptide research
Our Pipeline

BZ371A Development

Revolutionary non-hormonal peptide therapy advancing through parallel clinical trials for both men and women

Latest Updates

News & Events

BZ371A Phase II Results
May 2025

BZ371A Phase II Trial Shows Outstanding Results in Post-Prostatectomy ED

Another Day Pharma announces successful Phase II clinical trial results for BZ371A. Study of 74 men shows combination therapy achieved 38% success rate vs 4% with standard care alone—a 10× improvement.

"We are delighted that these trial results show that BZ371A is proving to be a well-tolerated, effective option" - Paulo Lacativa

Read Full Article →
BIO International Convention
June 2024

Another Day Pharma at BIO International

Join us at the world's largest biotechnology conference to discuss our innovative pipeline and partnership opportunities.

Laboratory research
April 2025

Clinical Trial Milestone

BZ371A reaches 74-patient enrollment target ahead of schedule, demonstrating strong patient interest in innovative ED treatment.

Read More →
Amino acid structure
March 2024

Peptide Innovation

New insights into peptide structure reveal enhanced therapeutic potential for sexual health.

Read More →

Get in Touch

Interested in learning more about our research, partnership opportunities, or career openings?

Location 2 Lakeview Stables, St Clere, Sevenoaks TN15 6NL, United Kingdom

We'd love to hear from you. Click below to send us a message and we'll get back to you as soon as possible.